GoldenGolden
Sangamo Therapeutics

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

Sangamo Therapeutics is a biotechnology company developing gene and cell therapies using genetic engineering that is headquartered in Richmond, California and founded in 1995 by Edward Lanphier.

Sangamo uses zinc finger nuclease technologywhere a class of proteins called zinc finger DNA-binding proteins (ZFPs), recognize and bind to specific sequences of DNA . In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

In an agreement between Sangamo and Mogrify, the later company’s cell conversion technology will be applied to generate regulatory T cells from pluripotent stem cells and embryonic stem cells. Sangamo aims to apply its ZFP gene engineering technology to Tregs as allogeneic cell therapies to treat inflammatory and autoimmune diseases.

Funding
Grant

On February 7, 2018 Sangamo Therapeutics received a grant worth $11 million from the National Institutes of Health (NIH).

Timeline

1995
Sangamo Therapeutics was founded by Edward Lanphier.

Funding rounds

People

Name
Role
LinkedIn

Stephane Boissel

Executive Vice President Corporate Strategies

Heather Turner, JD

Senior Vice President and General Counsel

Sandy Macrae, M.B., Ch.B., Ph.D

CEO

Further reading

Title
Author
Link
Type
Date

AP Exclusive: US scientists try 1st gene editing in the body

Marilynn Marchione

Web

Man 'cured' of HIV through gene editing holds hope for others

Associated Press

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

TxCell

News

Title
Author
Date
Publisher
Description
May 24, 2021
BioSpace
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 19, 2021
BioSpace
- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer -

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.